All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The latest on venetoclax combinations in AML from ASH 2021
The BCL-2 inhibitor, venetoclax, has transformed the treatment landscape for acute myeloid leukemia (AML), particularly in cases where patients are considered ineligible for intensive...
Efficacy and safety of CLAD and LDAC plus VEN alternating with AZA in older patients with de novo AML
Acute myeloid leukemia (AML) develops mostly in older population and treatment options are restricted due to age and comorbidities in this...
"The AML Hub is a trusted, respected, and comprehensive resource where clinicians and researchers interested in AML can confidently learn about the most exciting and novel clinical and biological advances in the field."
Your opinion matters